ClinicalTrials.gg
CompletedNCT05015920Updated May 18, 2025

A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

An interventional study of BD211 Drug Product in Hematologic Diseases, sponsored by Shanghai BDgene Co., Ltd.. Completed at 1 site in China. Open to participants aged 5 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Shanghai BDgene Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
5 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Hematologic Diseases with a site in China — 19 open to participants now, 25 under way, 8 of them phase 3. Hematologic Diseases · China.

Enrollment
51st of 52
2 · median 62
Started
2021
with 8 others
No phase
12 of 65
5 open now
Registered
26th of 65
by date

Among the 65 studies in Hematologic Diseases with a site in China, this one is the 51st largest by enrollment of the 52 interventional ones that give a count, is one of 9 that started in 2021, is one of 12 with no phase, and was the 26th registered.

Hematologic Diseases

610 studies on the registry are indexed under Hematologic Diseases; 109 are open to participants now.

Browse Hematologic Diseases studies →

Open to participants now

19 of the 65 studies in Hematologic Diseases with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 73 Hematologic Diseases studies recruiting now, 46 (63%) set no upper age limit and 23 (32%) stop at 75 or younger; 28 take children under 18; 4 take healthy volunteers.

This study: 5 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hematologic Diseases with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.

Read the detailed description

After collection of mobilised peripheral blood samples, the patient's autologous cells,enriched for CD34+ HSCs, undergo ex vivo transduction with lentiviral vector encoding βA-T87Q-globin to BD211 finished product,which is then infused intravenously into the patient after myeloablative busulfan conditioning to prepare bone marrow "niches" for engraftment of the HSCs.

After discharge, subjects will be followed monthly, at a minimum, for 6 months and thereafter every 3 months for the remainder of the 24 months post-transplant.

Evaluation will include Routine and special biological testing at regular intervals, collection of AEs and concomitant medications, and evaluation of disease specific biological and clinical parameters.

Subjects will then be enrolled in a long-term follow-up protocol with annual evaluations for an additional 13 years post-transplant.

The long-term follow-up study will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.

This study will end when the last subject completes the Month 24 visit or discontinues from the study.

03

Conditions studied

  • Hematologic Diseases

Browse trials for

Keywords

  • TDT
  • β-thalassemia major
04

Who can participate

Ages eligible
5 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 5 to 35 years of age.
  2. Be eligible for HSCT based on institutional medical guideline, but without a matched related donor.
  3. Transfusion-dependent β-Thalassemia Major, regardless of the genotype, with the diagnosis confirmed by studies. Subjects must be stable and maintained on an appropriate iron chelation regimen. Transfusion dependence is defined as requiring at least 100 mL/kg/year of packed red blood cells(pRBCs).
  4. Have been treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.
  5. Be willing and able, in the Investigator's opinion, to comply with the study procedures outlined in the study protocol. If a pediatric subject, the subject's parent/legal guardian also must be willing and able to comply with the study procedures outlined in the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Availability of a willing matched HLA-identical sibling hematopoietic cell donor.
  2. Positive for presence of , human T-lymphotropic virus, vesicular stomatitis virus G antibody.
  3. , active bacterial, viral, fungal, or parasitic infection.
  4. A white blood cell (WBC) count\<3x109/L and/or count\<120x109/L
  5. Receipt of an transplant.
  6. Receipt of erythropoietin within 3 months before HSCT harvest.
  7. to anesthesia for bone marrow harvesting.
  8. Any of prior or current , myeloproliferative or immunodeficiency disorder.
  9. Active relapsing malaria
  10. Immediate family member with a known or suspected Familial Cancer Syndrome.
  11. Diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study.
  12. Pregnancy or breastfeeding in a postpartum female or absence of adequate for fertile subjects.
  13. Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician.
  14. History of major organ damage.including Liver, Heart, Kidney disease, pulmonary hypertension ,severe iron overload, which in the opinion of the physician is grounds for exclusion.
  15. Participation in another clinical study with an drug within 30 days of screening.
  16. Hydroxyurea therapy within 3 months before hematopoietic stem cell collection.
  17. An assessment by the Investigator that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
  18. Subjects who have the desire to become a parent within the 27-month study period.
  19. Prior receipt of gene therapy.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Mobilization,harvest,transduction,conditioning,treatment,engraftment

    Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.

    Genetic: BD211 Drug Product

Interventions

  • GeneticBD211 Drug Product

    Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.

06

What researchers measure

Primary outcomes

  1. Evaluate the success and kinetics of HSC engraftment.

    Three consecutive absolute neutrophil counts≥500 cells/uL, three consecutive platelet values ≥20 e9/L, measure blood samples monthly after BD211 drug product infusion.

    Time frame: At multiple timepoints after infusion for 24 months.

  2. Incidence of transplant-related mortality through 100 days post-transplant.

    Incidence of transplant-related mortality through 100 days post-transplant.

    Time frame: Up to 100 days post-HSCT.

  3. Overall survival of maintenance phase.

    Overall survival up to 24 months post-HSCT.

    Time frame: Up to 24 months post-HSCT.

  4. Post-transplant blood samples for replication competent lentivirus (RCL) testing.

    The testing of any subject positivity will be considered an SAE and suspend the inclusion of new subjects.

    Time frame: At multiple timepoints after infusion for 24 months.

  5. Assessment of Clonal dominance or leukemia/lymphoma and other malignancies.

    Using peripheral blood of subjects for integration site analysis via LAM-PCR \& deep sequencing.

    Time frame: At multiple timepoints after infusion for 24 months.

  6. Incidence of treatment- related adverse events.

    According to the requirements of the National Cancer Institute Common Terminology Standards for Adverse Events (NCI CTCAE) version 5.0, monitor laboratory parameters and the frequency and severity of clinical AEs.

    Time frame: Up to 24 months after BD211 drug product infusion.

Secondary outcomes

  1. Quantify gene transfer efficiency and expression of BD211 drug product.

    Expression of βA-T87Q-globin chain in whole blood by assessing the ratio of βA-T87Q-globin to α-globin, as well as βA-T87Q-globin fractions in all β-chains over time by HPLC.

    Time frame: Up to 24 months after engraftment.

  2. Quantify the hematopoietic chimerism resulting from treatment with BD211 drug product.

    Measuring lentiviral vector copy number per diploid genome(c/dg) for evaluation.

    Time frame: Up to 24 months after engraftment.

  3. HbAT87Q in peripheral blood

    Measure the effects of transplantation with BD211 on the expression of disease-specific biological parameters and clinical events, including amounts of HbAT87Q in peripheral blood in grams per deciliter (g/dL).

    Time frame: Up to 24 months after engraftment.

  4. Reduction of RBC transfusion requirements from baseline

    Reduction from baseline of RBC transfusion requirements (mL/kg) per month and year post-transplant, Up to 24 months after engraftment.

    Time frame: Up to 24 months after engraftment.

  5. Duration of transfusion independence (months).

    Duration of transfusion independence up to 24 months after engraftment.

    Time frame: Up to 24 months after engraftment.

  6. Weighted average Hemoglobin

    Weighted average Hemoglobin during transfusion independence in grams per deciliter (g/dL), up to 24 months after engraftment.

    Time frame: Up to 24 months after engraftment.

  7. Changes of liver iron burden from baseline

    Changes from baseline in iron burden by assessing liver iron content (mg Fe/g dry weight).

    Time frame: Up to 24 months after engraftment.

  8. Changes of cardiac iron burden from baseline

    Changes from baseline in iron burden by assessing cardiac iron content using magnetic resonance imaging (MRI) T2\* value (milliseconds, ms).

    Time frame: Up to 24 months after engraftment.

07

Study locations

1 site
  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
    Kunming, Yunnan 650000, China
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Aug 2024, 37 months.

Of 54 interventional studies with no phase under Hematologic Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 47. This study's 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Aug 23, 2021
StartActual
Jul 10, 2021
Primary completionActual
Aug 23, 2024
CompletionActual
Dec 31, 2024
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015920
Lead sponsor
Shanghai BDgene Co., Ltd.
Collaborators
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Responsible party
Sponsor
First posted
Aug 23, 2021
Start date
Jul 10, 2021
Primary completion
Aug 23, 2024
Completion
Dec 31, 2024
Last update
May 18, 2025

Study contacts

Sanbin Wang, Dr.
study chair · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion